Genomate Health

Genomate Health is a precision oncology company that has developed Genomate®, the world's first clinically proven AI-powered clinical decision support system for personalized cancer treatment. The platform analyzes each patient's unique genetic alterations and biomarkers from their NGS report to rank targeted therapies based on the totality of their molecular information — not just a single mutation. Clinically, Genomate-recommended treatments have shown 4x higher positive response rates in the SHIVA01 trial, 2.6x longer overall survival and 3x longer progression-free survival in lung cancer, and matched 72% of pediatric cancer patients with actionable targeted treatments. Genomate serves oncologists, biopharma companies, payers, cancer centers, and labs. The company is a spin-out of Oncompass Medicine (founded 2003) and was incorporated in 2022 as a member of CancerX, a White House initiative, and a graduate of Mayo Clinic Platform_Accelerate. In January 2026, Genomate Health acquired Oncompass Medicine to expand its global footprint.